GTC Biotherapeutics (fka GTCB)

[keitern]

I think their plans are to raise roughly 28mil in cash through financing and/or partnerships annually for the next several years. The financing environment will not always be this tough presumably. The additional money from sales (over and above cogs) of Atryn will go towards expanded development going forward.
I think the idea is to do as much as possible with about 7mil/qtr on avg. and so far they have done quite a bit with it. It's just disappointing that the market doesn't value it very highly at this point.